Allogenic Umbilical Cord Blood Plasma combined with Mononuclear Cells (UCB-PM)

  • The FDA has verified the lab from which Adia Labs sources its stem cell product “Adia Vita” to ensure that each milliliter contains a minimum of 100 million umbilical cord stem cells and 3 trillion exosomes.
  • Description: UCB-PM is an allogeneic, minimally manipulated product derived from allogenic umbilical cord blood collected from normal healthy planned cesarean section donors. We have completed extensive characterization of the final UBP-PM product to elucidate the regenerative compartments mediating our observed therapeutic effect.
  • Adia Vita’s manufacturer’s methodology is designed to preserve the naturally-occurring soluble proteins and nanoparticles including exosomes present in full-term cord blood UCB-PM. Therefore, we have characterized these two distinctly and therapeutically important components.
  • There is no addition or combination of any other substance of diluent to the Adia Vita product during production besides the cryopreservation solution dimethyl sulfoxide (DSMO)
  • Each 1.0 ml Vial of Adia Vita is guaranteed to have > 100 million Stem Cells and > 3 Trillion Exosomes 

*Investigational New Drug authorization by FDA is done only after intense scrutiny and testing to prove Safety and effectiveness. 

Adia Labs products are distributed for analytical testing and/or research use purposes and/or use with an FDA approved Investigational New Drug (IND) application, or other Institutional Review Board (IRB) approved protocols or similar. The use with patients should include full disclosure and a signed consent form

What is UCB-PM?

Allogenic Umbilical Cord Blood Plasma combined with Mononuclear Cells refers to a type of therapeutic approach or treatment that uses components derived from umbilical cord blood for medical purposes, often in the context of regenerative medicine, immunotherapy, or cell-based therapies.

Allogenic

This term means that the cells or tissue are derived from a donor (not the patient receiving the treatment). In this case, it refers to the use of umbilical cord blood collected from a donor, not the patient’s own blood.

Umbilical Cord Blood Plasma

The umbilical cord is rich in stem cells, plasma, and other regenerative factors. Plasma is the liquid component of blood, and it contains nutrients, hormones, and waste products. Cord blood plasma refers to the plasma portion of the blood extracted from the umbilical cord at birth.

Mononuclear Cells

These are cells that have a single nucleus (compared to other cells with multiple nuclei). In the context of cord blood, these cells usually include hematopoietic stem cells (which can develop into different types of blood cells), mesenchymal stem cells (which have regenerative properties), and various other immune cells. These cells are important because they can support tissue regeneration, repair, and immune modulation.

Why combine these components?

  • Umbilical cord blood and its components are often used in cell therapies because they are rich in regenerative stem cells and immune-modulating factors. The plasma helps create a favorable environment for cell growth, while the mononuclear cells contribute to healing, immune modulation, and potentially tissue regeneration.
  • This combination is commonly explored in clinical trials for various conditions like autoimmune diseases, chronic inflammation, neurological disorders, and even some cancers.

Potential Applications:

  • Regenerative Medicine: Repairing damaged tissues and organs, especially in cases where the body’s natural healing is impaired.
  • Immune Modulation: Helping the body’s immune system recover or behave in a more balanced way, which could be beneficial in conditions like autoimmune diseases or inflammatory disorders.
  • Hematopoietic Disorders: Since umbilical cord blood contains stem cells, it has been used in stem cell transplants, especially for patients with blood-related disorders like leukemia or lymphoma.

For example, this therapy could be used for regenerative medicine applications where the aim is to promote healing or replace damaged tissue. It’s also being investigated for its potential in immunotherapies, where the cells may help to modulate the immune system in diseases like graft-versus-host disease (GVHD), certain types of cancer, or autoimmune disorders.

Want To Learn More?

If you have any questions about our research, ongoing clinical trials, or the potential applications of our therapies, please don’t hesitate to reach out. Whether you’re a healthcare professional, a patient, or simply curious about the possibilities of regenerative medicine, our team is here to provide you with the information you need. Please fill out the form, and one of our specialists will get back to you as soon as possible.